Barratt

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Rider Drains Say Boots and Tesco’s Decision to Stop Selling Plastic-Based Wet Wipes Will Help UK Drainage and Reduce Environmental Damage

Retrieved on: 
Thursday, May 5, 2022 - 2:00pm

Today, Paul Rider, managing director of Rider Drains , is applauding the decision announced by UK retailer Boots, in which theyve committed to stop selling wet wipes containing plastic fibres by the end of 2022.

Key Points: 
  • Today, Paul Rider, managing director of Rider Drains , is applauding the decision announced by UK retailer Boots, in which theyve committed to stop selling wet wipes containing plastic fibres by the end of 2022.
  • Rider Drains have advised customers to avoid plastic-based toiletries and wet wipes for many years as they cause incomprehensible damage to the environment, not to mention drainage systems.
  • Below, we outline why Rider Drains have strenuously advocated the use of biodegradable toiletries and wet wipes.
  • With an estimated 11 billion wet wipes sold in the UK each year, wet wipes are still being flushed away.

Novatech Promotes Kim "KJ" Barratt to Chief Human Resources Officer

Retrieved on: 
Tuesday, February 22, 2022 - 1:31pm

NASHVILLE, Tenn., Feb. 22, 2022 /PRNewswire/ -- Managed Office pioneer Novatech has promoted Kim "KJ" Barratt to Chief Human Resources Officer (CHRO).

Key Points: 
  • NASHVILLE, Tenn., Feb. 22, 2022 /PRNewswire/ -- Managed Office pioneer Novatech has promoted Kim "KJ" Barratt to Chief Human Resources Officer (CHRO).
  • In nearly six years with Novatech, KJ has progressed through several significant roles, most recently serving as Vice President of Administration.
  • In her new assignment, KJ reports directly to Novatech CEO Dan Cooper and will oversee the following for Novatech:
    "Throughout her Novatech career, KJ has implemented practices and processes that contributed to the company's outstanding growth," said Novatech CEO Dan Cooper.
  • Offering a full Managed Office portfolio, Novatech simplifies and streamlines the technology experience for today's business.

Elliott Advisors Publishes Letter on Taylor Wimpey

Retrieved on: 
Friday, December 10, 2021 - 2:20pm

Dear Members of the Board:

Key Points: 
  • Dear Members of the Board:
    We are writing to you on behalf of funds advised by Elliott Advisors (UK) Limited (Elliott or we), which together are one of the top five investors in Taylor Wimpey plc (Taylor Wimpey or the Company).
  • The purpose of todays letter is to share our perspectives on the opportunity at Taylor Wimpey.
  • Taylor Wimpey today is one of the top-three homebuilders in the U.K. by number of completions.
  • Elliott Advisors (UK) Limited is an affiliate of Elliott Investment Management L.P.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005308/en/

Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021

Retrieved on: 
Thursday, November 4, 2021 - 8:05pm

In the Phase 2a randomized, placebo-controlled JANUS trial in 16 IgAN patients, serum galactose-deficient IgA1 (Gd-IgA1) was assessed at baseline, weeks 4, 12, 24, 48, and 72.

Key Points: 
  • In the Phase 2a randomized, placebo-controlled JANUS trial in 16 IgAN patients, serum galactose-deficient IgA1 (Gd-IgA1) was assessed at baseline, weeks 4, 12, 24, 48, and 72.
  • Results showed that atacicept, administered subcutaneously once weekly, demonstrated a substantial reduction in serum Gd-IgA1 in a dose-dependent manner that was durable through 72 weeks.
  • The presentation titled, Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients, was included in the session entitled, Glomerular Disease: Treatment and Outcomes (PO1203-3).
  • The Phase 2a JANUS trial was the first study to show substantial Gd-IgA1 reduction with atacicept in IgAN patients, said Professor Barratt.

Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021

Retrieved on: 
Thursday, November 4, 2021 - 5:05pm

Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).

Key Points: 
  • Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
  • Patients in Cohort 1 received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.
  • Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.
  • BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy.

MX Welcomes Lexi Hall as Director of Public Policy

Retrieved on: 
Wednesday, May 19, 2021 - 2:00pm

b'WASHINGTON and SILICON SLOPES, Utah, May 19, 2021 /PRNewswire/ --MX, the leader in modern connectivity and data enhancement for financial institutions, fintechs and organizations everywhere, today announced that Lexi Hall has joined the company as Director of Public Policy.

Key Points: 
  • b'WASHINGTON and SILICON SLOPES, Utah, May 19, 2021 /PRNewswire/ --MX, the leader in modern connectivity and data enhancement for financial institutions, fintechs and organizations everywhere, today announced that Lexi Hall has joined the company as Director of Public Policy.
  • Hall will oversee the company\'s public policy initiatives, including federal, state and local government relations.
  • She will report to MX Chief Advocacy Officer Jane Barratt.\n"Lexi Hall brings a wealth of experience to MX as a data expert and policy advisor for the U.S. Senate Banking Committee and we are thrilled to welcome her to the team," said Jane Barratt, Chief Advocacy Officer, MX.
  • The U.S. is poised for true regulatory innovation in the financial data space and I\'m thrilled to be joining the MX team to help drive this innovation," said Lexi Hall, Director of Public Policy, MX.

Baraja appoints ex-Intel, Google networking pioneer Craig Barratt to board of directors

Retrieved on: 
Friday, March 19, 2021 - 6:29am

Baraja , creator of breakthrough Spectrum-Scan LiDAR technology, today appointed networking industry veteran Craig Barratt, PhD, to the Board of Directors, as the company expands commercial partnerships and deployments globally.

Key Points: 
  • Baraja , creator of breakthrough Spectrum-Scan LiDAR technology, today appointed networking industry veteran Craig Barratt, PhD, to the Board of Directors, as the company expands commercial partnerships and deployments globally.
  • Over the past 20 years, he has held senior executive positions at Google where he managed the Google Fiber rollout initiative.
  • Were extremely excited to have Craig join the team and help advise us on the next stage in our journey.
  • Baraja is the rare type of company thats managed to create a simple solution to a complex problem, Barratt said.

IonQ Announces CFO, Chief Legal Officer, and Board Appointments

Retrieved on: 
Monday, March 8, 2021 - 1:00pm

Joining IonQ are Thomas Kramer, Chief Financial Officer and Salle Yoo, Chief Legal Officer and Corporate Secretary.

Key Points: 
  • Joining IonQ are Thomas Kramer, Chief Financial Officer and Salle Yoo, Chief Legal Officer and Corporate Secretary.
  • Now, at IonQ, his focus will be to commercialize the company's infrastructure and prepare IonQ for its debut on the public market.
  • "As an investor and advisor, I know what it takes to build an impactful business," said IonQ Chief Legal Officer Salle Yoo.
  • In addition, IonQ is thrilled to announce additions to its board of directors, including:
    Craig Barratt, Independent Board Member.

Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

Retrieved on: 
Tuesday, May 19, 2020 - 1:15pm

Members of the Aduro executive team will be joined by Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester.

Key Points: 
  • Members of the Aduro executive team will be joined by Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester.
  • To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro's website at www.aduro.com .
  • To access a recording of the conference call, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and enter the Conference ID 8568238.
  • Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline.